Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure

Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab. Novartis paid $1.4B for drug via Tourmaline Bio.

Raccontata daendpoints.news